TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24067390

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) users
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-OCP users
Number of subjects: 100
Study: 21851939

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg on cycle days 3-7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg on cycle days 5-9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fertile ovulatory women (control group)
Number of subjects: 15
Study: 19525519

Group type: EXPERIMENTAL
Intervention: sirolimus 2 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 50
Study: 17200148

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4922

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4922
Study: 15132761

Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 microg/kg, i.m.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 10
Study: 11983670

Group type: EXPERIMENTAL
Intervention: alfentanil-propofol
Number of subjects: 140

Group type: COMPARATOR
Intervention: fentanyl-propofol
Number of subjects: 140
Study: 9613475

Group type: EXPERIMENTAL
Intervention: Active group (engaged in discussion about guidelines)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Passive group (attended a lecture)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (received neither guidelines nor educational contact)
Number of subjects: 191
Study: 7641905

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) alone (0.625 mg daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conjugated estrogens (CE) plus medrogestone (5 mg during the last 12 days of each 28-day cycle)
Number of subjects: 114
Study: 2653402

Group type: EXPERIMENTAL
Intervention: colchicine 0.5 mg bd for 1 week
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 943169

Group type: EXPERIMENTAL
Intervention: Urea-lactic acid ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Base ointment
Number of subjects: 0
Study: 31563959

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 669
Study: 29550911

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus acidophilus LA‐5 plus Bifidobacterium animalis subsp. lactis BB‐12)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 54
Study: 28537654

Group type: EXPERIMENTAL
Intervention: Ecological immune-enhanced enteral nutrition (EIEN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 54
Study: 25514700

Group type: EXPERIMENTAL
Intervention: Hypromellose 2%
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (simulation of the procedure)
Number of subjects: 38
Study: 22878879

Group type: EXPERIMENTAL
Intervention: Short-form Sun-style t'ai chi (SSTC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (usual medical care)
Number of subjects: 42
Study: 21922877

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18940881

Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate (67.5 mmol/d)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo (no bicarbonate)
Number of subjects: 171
Study: 16499489

Group type: EXPERIMENTAL
Intervention: Single dose of long-acting naltrexone 380 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Multiple doses of long-acting naltrexone 380 mg every 28 days for a total of 4 doses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral naltrexone 50 mg daily for 5 days followed by IM long-acting naltrexone 380 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oral naltrexone 50 mg
Number of subjects: 42
Study: 15082472

Group type: COMPARATOR
Intervention: Information booklet
Number of subjects: 296

Group type: COMPARATOR
Intervention: Low sodium, high potassium salt
Number of subjects: 296

Group type: COMPARATOR
Intervention: Lifestyle prompts for high fruit, vegetable, fibre; and low fat
Number of subjects: 296
Study: 11360489

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine administered sublingually with a hole in it
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine administered intranasally with a syringe
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine administered orally (contents administered orally)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine (capsule bitten and swallowed)
Number of subjects: 6
Study: 9282082

Group type: EXPERIMENTAL
Intervention: Experimental group (intervention plan to promote positive attitudes toward lactation)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 202
Study: 8499937

Group type: EXPERIMENTAL
Intervention: Slurried bananas (SL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Solid bananas (SO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Artificially sweetened placebo drink (P)
Number of subjects: 8
Study: 2949583

Group type: COMPARATOR
Intervention: PN 200-110 (isradipine)
Number of subjects: 50
Study: 29931216

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg subcutaneously monthly for 12 months
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 26285021

Group type: EXPERIMENTAL
Intervention: STAND
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: WALK
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CYCLE
Number of subjects: 9

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 9
Study: 24398732

Group type: EXPERIMENTAL
Intervention: Simulator training using a transesophageal echocardiography‐mannequin simulator
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traditional didactic training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Simulator training for clinical anesthesia‐1 residents
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Simulator training for residents with no previous transesophageal echocardiography experience
Number of subjects: 42
Study: 23594003

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study: 20018587

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration on stable support
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration on sway-referenced support
Number of subjects: 20

Group type: COMPARATOR
Intervention: No vibration on stable support
Number of subjects: 20

Group type: COMPARATOR
Intervention: No vibration on sway-referenced support
Number of subjects: 20
Study: 18676897

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 234

Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 234
Study: 16200586

Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ) at 100 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Chloroquine diphosphate (CDP) at 250 mg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clofazimine (CFZ)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Chloroquine diphosphate (CDP)
Number of subjects: 33
Study: 12843154

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 968
Study: 10895850

Group type: EXPERIMENTAL
Intervention: Repaglinide/troglitazone combination therapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Repaglinide monotherapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Troglitazone monotherapy
Number of subjects: 256
Study: 8795325

Group type: EXPERIMENTAL
Intervention: Injection pressure of 250 g.cm‐2 (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Injection pressure of 140 g.cm‐2 (group 1)
Number of subjects: 50
Study: 1354566

Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg (Triludan Forte)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg (Zirtek)
Number of subjects: 0

Group type: COMPARATOR
Intervention: loratadine (Clarityn)
Number of subjects: 0
Study: 6359989

Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline (32.5 micrograms)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day) plus placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day) plus terbutaline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28937862

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate (Nutricia Preop; n = 45)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (water flavored with lemon; n = 46)
Number of subjects: 91
Study: 26957222

Group type: EXPERIMENTAL
Intervention: Resistance training program (dumbbell mass-adjusted to 80% of the 1-repetition maximum, performed 3 days a week for 6 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 23
Study: 23775598

Group type: EXPERIMENTAL
Intervention: Lecithinized curcumin (Meriva)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 23327031

Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 80
Study: 20861172

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: rs12325817 alleles (0, 1, 2) in premenopausal women
Number of subjects: 49
Study: 18551884

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 16111583

Group type: EXPERIMENTAL
Intervention: 125I vs. 103Pd alone (n = 290)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: 103Pd with 20 Gy vs. 44 Gy supplemental external beam radiotherapy (n = 213)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Moderate rectal radiation doses
Number of subjects: 503
Study: 12825239

Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg, three times per day for three months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (administered three times per day for three months)
Number of subjects: 100
Study: 10993857

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 35
Study: 8869661

Group type: EXPERIMENTAL
Intervention: Smoking three cigarettes per hour during a 5.5-hour period
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-smoking day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 9
Study: 1900383

Group type: EXPERIMENTAL
Intervention: Diet M (70 g sunflower margarine, P:S 1.1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet B (70 g butter, P:S 0.2)
Number of subjects: 0
Study: 6860528

Group type: EXPERIMENTAL
Intervention: Diclofensine 25 mg and 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nomifensine 75 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 31735591

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine preparation (single application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily treatment for 5 days with 10% povidone iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 31285147

Group type: EXPERIMENTAL
Intervention: Opicinumab 3 mg/kg
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Opicinumab 10 mg/kg
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Opicinumab 30 mg/kg
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Opicinumab 100 mg/kg
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 28042038

Group type: EXPERIMENTAL
Intervention: Appetitive food cue condition
Number of subjects: 119

Group type: COMPARATOR
Intervention: Non-food cue condition
Number of subjects: 119
Study: 27045864

Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 24914426

Group type: EXPERIMENTAL
Intervention: Fluor Protector (0.1% fluoride varnish)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cervitec Plus (1% chlorhexidine‐1% thymol varnish) + Cervitec Gel (0.2% chlorhexidine‐0.2% sodium fluoride)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (toothbrushing only)
Number of subjects: 90
Study: 22076422

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg, ezetimibe 10mg (Group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard therapy (Group S)
Number of subjects: 89
Study: 20618556

Group type: EXPERIMENTAL
Intervention: Triple peptide complex (TPC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17123687

Group type: EXPERIMENTAL
Intervention: Simplified protocol
Number of subjects: 117

Group type: COMPARATOR
Intervention: MPDS v11.2 protocol
Number of subjects: 117
Study: 11128860

Group type: EXPERIMENTAL
Intervention: 38 mg x kg(‐1) x d(‐1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0 mg x kg(‐1) x d(‐1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 76 mg x kg(‐1) x d(‐1)
Number of subjects: 37
Study: 9191523

Group type: COMPARATOR
Intervention: Recombinant interferon-alpha (IFN-alpha) at a dose of 3 MU given intramuscularly 3 times a week for 6 months with a 1-month interval between cycles.
Number of subjects: 0
Study: 1554195

Group type: EXPERIMENTAL
Intervention: ICI 204219 (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3927279

Group type: EXPERIMENTAL
Intervention: Metoclopramide (dopamine receptor blocker)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Starvation
Number of subjects: 6
Study: 29394147

Group type: EXPERIMENTAL
Intervention: Essen test group
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Zagreb test group
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Essen control group
Number of subjects: 1944
Study: 26769143

Group type: EXPERIMENTAL
Intervention: mfERG at 5 min after flash fundus photography (FFP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: mfERG at 15 min after flash fundus photography (FFP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: mfERG at 30 min after flash fundus photography (FFP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: mfERG at 45 min after flash fundus photography (FFP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: mfERG without flash fundus photography (FFP)
Number of subjects: 10
Study: 24323615

Group type: EXPERIMENTAL
Intervention: Quadrantectomy with axillary lymph node dissection (QUAD)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Quadrantectomy without axillary lymph node dissection (QU)
Number of subjects: 517
Study: 22435864

Group type: EXPERIMENTAL
Intervention: Public health promotion specialist (PHPS) intervention providing a 5‐ to 10‐minute presentation about exercise, heart health, healthy eating on a budget, or weight control.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving usual ED care.
Number of subjects: 0
Study: 20585108

Group type: EXPERIMENTAL
Intervention: KNO3 capsules (4 mmol, 12 mmol, or 24 mmol)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Beetroot juice (250 mL, 5.5 mmol nitrate)
Number of subjects: 35

Group type: COMPARATOR
Intervention: KCl (24 mmol)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Water (250 mL)
Number of subjects: 35
Study: 18568474

Group type: EXPERIMENTAL
Intervention: Ice-cream containing Bifidobacterium lactis Bb-12
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control ice-cream without viable bacteria
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study: 16353677

Group type: EXPERIMENTAL
Intervention: Preoperative shaving (razor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hair removal by clipper or depilatory cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of hair removal immediately before surgery
Number of subjects: 0
Study: 12050273

Group type: EXPERIMENTAL
Intervention: Vitamin C (24 mg/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 10
Study: 10690807

Group type: EXPERIMENTAL
Intervention: Co-culture of human embryos on Vero cells
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Embryos transferred on days 5 or 6
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Frozen-thawed co-cultured blastocysts
Number of subjects: 384

Group type: COMPARATOR
Intervention: Conventional day 2 replacements
Number of subjects: 384
Study: 8721040

Group type: EXPERIMENTAL
Intervention: Strawberry flavor of ondansetron syrup
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Grape flavor of ondansetron syrup
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: No flavor preference
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 59
Study: 1757609

Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.1% diflucortolone valerate ointment
Number of subjects: 120
Study: 31191100

Group type: EXPERIMENTAL
Intervention: Nondominant group (practicing exclusively on the nondominant side)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without any instruction regarding the practice side)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilateral group (practicing with both dominant and nondominant sides)
Number of subjects: 30
Study: 27631388

Group type: EXPERIMENTAL
Intervention: Center-based setting using RPE to guide exercise intensity
Number of subjects: 2622

Group type: EXPERIMENTAL
Intervention: Home-based setting using RPE to guide exercise intensity
Number of subjects: 2622

Group type: COMPARATOR
Intervention: Comparison of center-based and home-based settings
Number of subjects: 2622
Study: 25512466

Group type: EXPERIMENTAL
Intervention: Allopurinol 500 mg intravenous (ALLO)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo intravenous (CONT)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Allopurinol (ALLO)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (CONT)
Number of subjects: 222
Study: 23681034

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Inhalational anesthesia (IA) with sevoflurane
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TIVA with propofol (subgroup analysis)
Number of subjects: 33

Group type: COMPARATOR
Intervention: IA with sevoflurane (subgroup analysis)
Number of subjects: 33

Group type: COMPARATOR
Intervention: IA with sevoflurane
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TIVA with propofol
Number of subjects: 33
Study: 20802165

Group type: EXPERIMENTAL
Intervention: Written action plan coupled with a prescription (WAP-P)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Unformatted prescription (UP)
Number of subjects: 219
Study: 19166993

Group type: EXPERIMENTAL
Intervention: Mindful self-focus induction
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Distraction induction
Number of subjects: 76

Group type: COMPARATOR
Intervention: Rumination induction
Number of subjects: 76

Group type: COMPARATOR
Intervention: Habitual distraction
Number of subjects: 76

Group type: COMPARATOR
Intervention: Habitual mindfulness
Number of subjects: 76
Study: 17664863

Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16105056

Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 to 180 mg once daily)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 410
Study: 12200100

Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy (video, personalized child development information, supportive telephone calls)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Standard dissemination strategy (control group)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy
Number of subjects: 498
Study: 10199774

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 1 year
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a mean dose of 1 UI/day for 2 years
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 33
Study: 8568547

Group type: EXPERIMENTAL
Intervention: Tobramycin 150 or 300 mg administered intramuscularly (i.m.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tobramycin 300 mg administered intramuscularly (i.m.)
Number of subjects: 12
Study: 2269380

Group type: EXPERIMENTAL
Intervention: Topical MC 903 ointment (50 micrograms/g) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of topical MC 903 with UVB radiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Topical MC 903 alone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Combination with UVB)
Number of subjects: 20
Study: 6457309

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 31487718

Group type: EXPERIMENTAL
Intervention: NIV NAVA
Number of subjects: 40

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 40
Study: 28916664

Group type: EXPERIMENTAL
Intervention: Synchronous carotid endarterectomy + CABG
Number of subjects: 129

Group type: COMPARATOR
Intervention: Isolated CABG
Number of subjects: 129